ResMed (ASX:RMD) reported Thursday fiscal third-quarter earnings of $2.37 per diluted share on a non-GAAP basis, up from $2.13 per diluted share a year earlier.

On a GAAP basis, diluted earnings per share rose to $2.58 from $2.04 year on year, the filing said.

Analysts polled by Visible Alpha were expecting EPS of $2.22.

Revenue for the three months ended March 31 was $1.29 billion, up 8% from $1.19 billion in the same period last year. Analysts surveyed by Visible Alpha expected $1.27 billion.

The board declared a quarterly dividend of $0.053 per share, up from the $0.048 in the previous reported period, payable on June 12 to shareholders on record as of May 8.